, the California-based global health care company, said on Monday that antitrust authorities in Germany and Spain have cleared its acquisition of
The deal is still waiting for clearance from the U.S. Federal Trade Commission. Allergan said in a press release that both the companies are working with the FTC to complete divestiture of Inamed's license for Reloxin to facilitate antitrust approval.
Botox-maker Allergan in December signed a definitive agreement to buy Inamed, a maker of breast implants and dermatology treatments. Allergan will pay $84 in cash, or 0.8498 of a share, for each Inamed share.
This story was created through a joint venture between TheStreet.com and IRIS.